Bruce Simon

Bruce L. Simon has led Pearson, Simon & Warshaw, LLP to national prominence. Mr. Simon specializes in complex cases involving antitrust, consumer fraud and securities. He has served as lead counsel in many business cases with national and global impact. In 2013, Mr. Simon was chosen as one of the Top 100 attorneys in California by the Daily Journal. He received a CLAY award from California Lawyer magazine as one of the attorneys of the year for his work in the In re TFT-LCD (Flat Panel) Antitrust Litigation trial and settlements and was also selected as one of the seven finalists for Consumer Attorneys of California’s Consumer Attorney of the Year award. Mr. Simon was included in the Top 100 for Super Lawyers, and has been selected as a Super Lawyer ten years in a row. He also received a Trial Lawyer Excellence award in Chicago from the Law Bulletin for the settlement reached in In re Potash Antitrust Litigation (II). He has attained Martindale-Hubbell’s highest rating (AV) for legal ability and ethical standards. Mr. Simon was co-lead class counsel in In re TFT-LCD (Flat Panel) Antitrust Litigation, a case where he and the firm obtained $473 million in settlements. He was also co-lead trial counsel in that case and obtained an $87 million jury verdict before trebling. TFT-LCD is considered to be one of the largest antitrust MDL class actions in the United States. Mr. Simon was also co-lead counsel in In re Potash Antitrust Litigation (II), a case which challenged a decades old international cartel that controlled one of the primary ingredients in fertilizer. The case resulted in $90 million in settlements for the direct purchasers. Before the case settled, a panel of the Seventh Circuit reversed the trial court’s upholding of the complaint. However, in an en banc review by the Seventh Circuit, Mr. Simon presented oral argument and achieved a unanimous 8-0 decision denying the defendants’ motion to dismiss. The opinion issued by the Court is one of the most significant decisions regarding the scope of international antitrust conspiracies. Mr. Simon also recently represented a generic brand drug company in an individual case alleging that the brand name manufacturer had filed false citizens petitions to delay the entry of the generic drug unto the market. The case resulted in a significant confidential settlement right before trial.